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ABSTRACT
Objective To independently evaluate the impact of the
second phase of the Health Foundation’s Safer Patients
Initiative (SPI2) on a range of patient safety measures.
Design A controlled before and after design. Five
substudies: survey of staff attitudes; review of case notes
from high risk (respiratory) patients in medical wards;
review of case notes from surgical patients; indirect
evaluation of hand hygiene by measuring hospital use of
handwashing materials; measurement of outcomes
(adverse events, mortality among high risk patients
admitted to medical wards, patients’ satisfaction,
mortality in intensive care, rates of hospital acquired
infection).
Setting NHS hospitals in England.
Participants Nine hospitals participating in SPI2 and nine
matched control hospitals.
Intervention TheSPI2 interventionwas similar to theSPI1,
with somewhat modified goals, a slightly longer
intervention period, and a smaller budget per hospital.
Results One of the scores (organisational climate)
showed a significant (P=0.009) difference in rate of
change over time, which favoured the control hospitals,
though the difference was only 0.07 points on a five point
scale. Results of the explicit case note reviews of high risk
medical patients showed that certain practices improved
over time in both control and SPI2 hospitals (and none
deteriorated), but there were no significant differences
between control and SPI2 hospitals. Monitoring of vital
signs improved across control and SPI2 sites. This
temporal effect was significant for monitoring the
respiratory rate at both the six hour (adjusted odds ratio
2.1, 99% confidence interval 1.0 to 4.3; P=0.010) and 12
hour (2.4, 1.1 to 5.0; P=0.002) periods after admission.
There was no significant effect of SPI for any of the
measures of vital signs. Use of a recommended system for
scoring the severity of pneumonia improved from 1.9%
(1/52) to 21.4% (12/56) of control and from 2.0% (1/50)
to 41.7% (25/60) of SPI2 patients. This temporal change
was significant (7.3, 1.4 to 37.7; P=0.002), but the
difference in difference was not significant (2.1, 0.4 to
11.1; P=0.236). There were no notable or significant
changes in the pattern of prescribing errors, either over
time or between control and SPI2 hospitals. Two items of
medical history taking (exercise tolerance and
occupation) showed significant improvement over time,
across both control and SPI2 hospitals, but no additional
SPI2 effect. The holistic review showed no significant
changes in error rates either over time or between control
and SPI2 hospitals. The explicit case note review of
perioperative care showed that adherence rates for two of
the four perioperative standards targeted by SPI2 were
already good at baseline, exceeding 94% for antibiotic
prophylaxis and 98% for deep vein thrombosis
prophylaxis. Intraoperative monitoring of temperature
improved over time in both groups, but this was not
significant (1.8, 0.4 to 7.6; P=0.279), and there were no
additional effects of SPI2. A dramatic rise in consumption
of soap and alcohol hand rub was similar in control and
SPI2 hospitals (P=0.760 and P=0.889, respectively), as
was the corresponding decrease in rates of Clostridium
difficile and meticillin resistant Staphylococcus aureus
infection (P=0.652 and P=0.693, respectively). Mortality
rates of medical patients included in the case note
reviews in control hospitals increased from 17.3% (42/
243) to 21.4% (24/112), while in SPI2 hospitals they fell
from 10.3% (24/233) to 6.1% (7/114) (P=0.043). Fewer
than 8% of deaths were classed as avoidable; changes in
proportions could not explain the divergence of overall
death rates between control and SPI2 hospitals. There
was no significant difference in the rate of change in
mortality in intensive care. Patients’ satisfaction
improved in both control and SPI2 hospitals on all
dimensions, but again there were no significant changes
between the two groups of hospitals.
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ConclusionsMany aspects of care are already good or
improving across the NHS in England, suggesting
considerable improvements in quality across the board.
These improvements are probably due to
contemporaneous policy activities relating to patient
safety, including those with features similar to the SPI,
and the emergence of professional consensus on some
clinical processes. This phenomenon might have
attenuated the incremental effect of the SPI, making it
difficult to detect. Alternatively, the full impact of the SPI
might be observable only in the longer term. The
conclusion of this study could have been different if
concurrent controls had not been used.
INTRODUCTION
In the first phase of the Health Foundation’s Safer
Patients Initiative (SPI1) four hospitals in the United
Kingdom took part in an organisational intervention
to “transformorganisational approaches to delivering
safer care” designed andmentored by the Institute for
Healthcare Improvement (IHI) and implemented in
an 18 month period from the end of 2004.1We report
our evaluation of SPI1 in a companion paper.1 A sec-
ond phase of the intervention, known as SPI2, was
rolled out over 20 months from March 2007 to Sep-
tember 2008 inclusive. SPI2 included 20 UK hospi-
tals (10 in England and 10 in the other countries of the
UK) selected with a process similar to that used for
SPI1. The intervention itself was modelled on that
used for SPI1,1 with some modifications (box 1). A
full report including methodological and analytical
detail is available.2
METHODS
Our methods were similar to those used for the evalua-
tion of SPI1.2 As with SPI1, the SPI2 evaluation used a
series of linked substudies to address both generic fea-
tures of systems that might be expected to improve if a
general strengthening of organisational systems in
relation to patient safety occurred, and specific process
outcomes that were targeted specifically by SPI
interventions.
Framework for evaluation
Table 1 summarises the substudies; all made use of a
controlled before and after design.3 While no qualita-
tive data were collected in SPI2, all of the quantitative
studies undertaken in the SPI1 evaluation were repli-
cated. Additional quantitative substudies were added
to address SPI objectives not directly studied in our eva-
luation of SPI1.1 These included review of surgical case
notes to measure compliance with a set of evidence
based standards for perioperative surgical care; exami-
nation of outcome data from intensive care units to pro-
vide evidence relevant to effectiveness of SPI2methods
to improve adherence to evidence based guidelines for
critical care; assessment of consumption of soap and
alcohol hand rub in hospital trusts, alongwithmeasures
of rates of infection withClostridium difficile andmeticil-
lin resistantStaphylococcus aureus (MSRA) to provide evi-
dence on measures to reduce infections associated with
healthcare; and audit by two independent reviewers of
all deaths in our case note review.
Intervention and control sites
To take advantage of routinely collected data, we
focused on SPI2 hospitals in England only. One SPI2
hospital declined to participate in the evaluation,
Box 1: Differences between SPI1 and SPI2
 The hospitals were required to work with a partner organisation (a “buddy system”) and
encouraged to hold regular meetings between the lead implementation teams (10-12
people) from each site
 There was a longer period between dissemination of the preparatory materials
(December 2006) and the first “kick-off” session where the various teams came
together with the Institute for Healthcare Improvement to share experiences (March
2007)
 The financial package was smaller than in the case of SPI1; a mean of £270000
(€314000, $430000) per site, rather than £775000 (€900000, $1.2m)
 The adverse event target was revised from a reduction of 50% to a reduction of 30%
 SPI2 sought a 15% reduction in mortality rates; this was not an explicit SPI1 aim
 The routine use of β blockers in the surgical “bundle” was removed as this clinical
standard was contentious in the UK
Table 1 | Summary of substudies in evaluation of phase two
of Safer Patients Initiative (SPI2)
Substudy and topic Data source
Unit of
analysis
Staff survey*
Staff morale, culture, and
opinion
NHS national staff survey Staff
member
Quality of care: acute medical care*
In patients aged >65 with
acute respiratory disease
Case note reviews (both
explicit and implicit)
Patient
Quality of care: perioperative care*
In patients with total hip
replacement and open
colectomy
Explicit case note review Patient
Clinical process measures*
Use of consumables for hand
hygiene
National observation study
of effectiveness of national
“cleanyourhands”
campaign
Hospital
Outcomes
Adverse events in patients
aged >65 with acute
respiratory disease*
Holistic case note review Patient
Hospital mortality in patients
aged >65 with acute
respiratory disease*
Case note review Patient
Intensive care unit mortality† Routinedata from intensive
care national audit and
research centre
Hospital
Infection rates associated
with healthcare †
Routine data from Health
Protection Agency
Hospital
Patient satisfaction* NHS patient surveys Patient‡
*Data collected and analysed centrally
†Data collected by hospital staff, then analysed centrally.
‡In SPI1 unit of analysis was “hospital” as, in that case, we did not have
individual patient data.
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leaving nine available for study. Ninematched control
sites were selected with the criteria in box 2.
Table 2 gives details of control and SPI2 hospitals.
Control hospitals were selected and approached in
August 2007, seven months after the intervention had
started in SPI2 hospitals (and after it had been com-
pleted in SPI1 hospitals).
Substudies
We carried out five substudies (see table 1).
Staff surveys
Staff morale, attitudes, and the organisational climate
might be expected to change in response to SPI2. All
nine SPI2 study sites and nine control sites were
included in both the 2006 and 2008National Staff Sur-
veys, conducted between October and December in
each of these years. Methods were the same as those
used for the evaluation of SPI1,1 with a sample of 850
staff members per site, except that a further two new
relevant survey questions, not available for the SPI1
evaluation, were included.
Error rates/quality of acute medical care
We sought to assess improvement in error rates and
quality of care. We selected patients aged over 65
with acute respiratory disease admitted to acute medi-
cal wards as the focus for study for the same reasons as
in the SPI1 evaluation (high risk, error prone popula-
tion). The areas of review included both those specifi-
cally targeted by SPI2, such as vigilance in monitoring
sick patients and prescription error, and those that
might be expected to improve if an overall shift in orga-
nisational systems and culture related to patient safety
occurred, such as adherence to various tenets of evi-
dence based care. Case notes were processed and
audited with the same procedures and criteria used
for the SPI1 evaluation.
Case notes were collected over three epochs (time
periods). Observations before implementation of
SPI2 were spread over two epochs (epoch 1: October
2003 toMarch 2004; epoch 2: October 2006 toMarch
2007). Epoch 3 (October 2008 to March 2009) was
after the intervention. As described for SPI1, case
notes were reviewed by MG, with one in 10 re-
reviewed by BDF.
Using review against explicit criteria, we aimed to
analyse 15 sets of case notes from each control and
SPI2 hospital per epoch (810 in total). This provided
80% power to detect a 13 percentage point change in
staff compliance with a standard where baseline com-
pliance was 70%. In each month, from each epoch, we
selected from each hospital the case notes from the first
two or three patients who fulfilled the eligibility cri-
teria. As before, case notes were not examined in ser-
ies, allowing us to detect learning/fatigue effects
among reviewers.
In addition to the criterion based explicit review, a
specialist in general medicine (MC) with experience in
reviewing case notes (the principal reviewer) evaluated
each set holistically for evidence of errors and adverse
events. To measure reliability, an experienced trainee
in respiratory medicine (TN, the reliability reviewer)
independently re-evaluated a subset of notes (n=74).
Errors were analysed and categorised as in our SPI1
evaluation.1 In addition, each death was re-analysed
by a second reviewer (MCD), medically trained in
anaesthetics and public health (“blinded” to epoch
and group), who had experience as a reviewer for the
National Confidential Enquiry into Perioperative
Deaths.
Error rates/quality of perioperative care
Improving perioperative care was a specific goal of
SPI2. We selected patients undergoing two types of
major surgical operation (total hip replacement and
open colectomy) for study. We developed a set of
Box 2: Criteria for selection of control sites
 Only non-specialist acute hospitals in England were considered
 Control and SPI2 hospitals should have a similar directorate structure (as described in
the NHS national staff survey)
 Hospitals should have the same “foundation” or “non-foundation” status (to gain
foundation status a hospital must satisfy the government that it has the management
capacity to warrant greater operational autonomy)
 Hospitals should be similarly located in either urban or rural settings
 Once these criteria were satisfied, the hospital with the most similar size (usually
within 1000 staff) to the SPI2 hospital was selected as the control hospital
Table 2 | SPI2 and matched control hospitals in phase two of Safer Patients Initiative (SPI2)
Hospital No Beds (hospital, current) Area* Teaching status†
SPI2 hospitals
1 411 Rural Affiliated
2 455 Urban Nil
3 620 Urban/rural Nil
4 634 Urban Nil
5 688 Urban Teaching hospital
6 804 Urban Teaching hospital
7 668 Urban Teaching hospital
8 523 Urban Teaching hospital
9 566 Urban Affiliated
Matched control hospitals
1 475 Rural Nil
2 511 Urban Nil
3 618 Urban Teaching hospital
4 723 Urban/rural Nil
5 447 Urban/rural Affiliated
6 789 Urban Affiliated
7 988 Urban Affiliated
8 532 Urban/rural Nil
9 1036 Urban Affiliated
*Based on visual inspection of population density map.
†According to hospital website.
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explicit criteria for perioperative care (box 3) based on
IHI “bundles” (collections of carefully packaged evi-
dence based standards directed at a particular condi-
tion or clinical scenario) and published clinical
guidelines.4-7 Case notes were obtained from the nine
control and nine SPI2 hospitals. We used one epoch
before the intervention (epoch 2, October 2006 to
March 2007) for comparison with the epoch after the
intervention (epoch 3, October 2008 to March 2009).
We planned to analyse 10 sets of case notes from each
epoch (five of each type of surgical operation) to yield a
total sample of 360. To control for seasonal effects, the
case notes were spread across each time period (two a
month). The notes were processed (including anon-
ymisation) in the same way as the acute medical notes
(see above).
A medically trained reviewer (UN) reviewed the
case notes. The first 20 cases were read jointly by UN
and RL and discussed for training purposes. The notes
were partially scrambled over epochs to assess, and if
necessary control for, learning/fatigue effects. Agree-
ment between raters was measured by using 27 sets of
case notes reviewed by a second reviewer (AK), a sur-
gical trainee. The sample was sufficient to detect a 25
percentage point effect of SPI at 80% power given a
baseline rate of 50%.
Indirect measure of hand hygiene
Improving hand hygiene was a specific aim of SPI. A
separate UK initiative to improve hospital hand
hygiene—the “cleanyourhands” campaign8—was also
rolled out in England and Wales between December
2004 and June 2005 and continued in subsequent
years. It sought to make alcohol hand rub available at
the bedside, as well as posters on wards updated
monthly, and encouraged patients to ask staff to clean
their hands. We tested the hypothesis that SPI2 would
have an additional effect over that of “cleanyour-
hands.”
We collected monthly data from NHS Logistics on
consumption of soap and alcohol hand rub (as an indir-
ect measure of compliance with hand hygiene) as an
extension of theNationalObservational Study toEval-
uate the “Cleanyourhands” campaign (NOSEC).9
Data were collected on a monthly basis from July
2004 to September 2008. This spanned a period before
SPI (July 2004 to February 2007) and a period concur-
rent with the intervention (March 2007 to September
2008). To adjust for potential variations in
consumption because of hospital size, these data,
which were available at hospital trust level, were
expressed as a rate (in litres) per 1000 bed occupancy
days. Bed occupancy days were based on yearly
averages spanning financial years.10
Outcomes
Adverse events—SPI2 aimed to reduce adverse events by
30%. We identified adverse events using the holistic
review of acute medical case notes (see holistic review
above), andwe assessed the degree of preventability, as
in the evaluation of SPI1.1
Mortality among acute respiratory patients—SPI2 sought
to reduce hospital mortality by 15%. We compared
mortality among acute medical patients whose notes
were included in the explicit review from before and
after the intervention.
Mortality among patients in intensive care units—As a
further check on mortality, we assessed mortality in
intensive care using data from the case mix
programme.11 Run by the Intensive Care National
Audit and Research Centre (ICNARC), this pro-
gramme is a comparative audit. Data from the inten-
sive care units in all of the study hospitals were
available on a monthly basis for six months before
SPI2 (October 2006-March 2007) and for six months
after the intervention (October 2008-March 2009).
Data were available for the numbers of deaths and
expected numbers of deaths, which we then used to
calculate observed to expected mortality ratios. Data
were also available on twomean risk prediction scores:
the APACHE (acute physiological and chronic health
evaluation) II score12 and the ICNARC score13 for
patients admitted directly from a ward. We adjusted
for these covariates in the analysis.
Infection control—Several components of the SPI
related to infection control. We assessed rates of infec-
tion with C difficile and MRSA from data from the
Health Protection Agency on cases of C difficile and
diarrhoea associated with MRSA bacteraemia in the
study sites. Data on C difficile were available on a
three monthly basis for the period January 2004 to
June 2009. MRSA data were available every three
months from April 2001 to September 2009. The
data therefore spanned a period before the inter-
vention (April 2001 or January 2004 to March 2007),
a period concurrent with the intervention (April 2007
to September 2008), and a period after the intervention
(October 2008 to June 2009 or September 2009). As
required by the Health Protection Agency, the data
were expressed as rates per 1000 for C difficile and per
100 000 bed occupancy days for MRSA.
Patients’ satisfaction—An improvement in patients’
satisfaction was not a specific aim of SPI but might be
a feasible outcome if an overall improvement in hospi-
tal quality occurred. We analysed data from NHS
patient surveys with the same methods used in the
SPI1 evaluation. Data were collected in October to
December 2006 (before the intervention) andOctober
to December 2008 (after the intervention).
Box 3: Standards (criteria) for explicit review of perioperative care
 Administration of prophylactic antibiotics before incision
 The use of prophylactic deep vein thrombosis treatment (unless contraindicated),
which included pharmacological intervention (unfractionated or low molecular weight
heparin) or mechanical interventions (such as antithromboembolism stockings, foot
pumps, and sequential compression devices) or both
 Intraoperative monitoring of temperature (on at least one occasion)
 The use of “advanced methods” of pain control (epidural anaesthesia or analgesia
controlled by patient, or both)
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Statistical methods
When necessary wemodified themethods andmodels
used in the SPI1 analysis to accommodate the presence
of an additional epoch before the intervention. The
temporal change between epochs 1 and 2was included
as a fixed effect in the statistical models. As before, the
effect of the SPI was identified as the discrepancy
between the two armsof the study in the change experi-
enced from the periods before and after the inter-
vention. All patient level analyses were adjusted for
age and sex. When the data were a time series (as
opposed to the before and after data available in
SPI1), we used population averaged models (fitted
with generalised estimating equations), incorporating
hospital level random effects. Here cubic polynomials
were used tomodel temporal effects, with a third order
autoregressive correlation structure for the residuals.
In this context, the effect of SPI2 was assessed as an
interaction between time and study arm.An exchange-
able (rather than autoregressive) correlation structure
was used for the analysis of mortality data from inten-
sive care units, as this was available only for two non-
contiguous six month time slots, before and after the
intervention. All analysis was carried out in Stata v10.
RESULTS
Staff survey
In the nine SPI2 hospitals, the overall response rate in
the “before” survey was 53% (3957 of 7402 valid ques-
tionnaires returned). This rate remained the same for
the “after” survey (3940/7448). In the nine control hos-
pitals, the response rates were 50% (3634/7301) and
49% (3616/7424), respectively.
For only one of the 13 scores (organisational climate)
was there a significant (P<0.01) change over time
between the control hospitals and SPI2 hospitals
(table 3), which favoured the controls. The effect size
for the difference in change between the control and
SPI2 hospitals after adjustment for covariates was
modest, at 0.07 points on a 5 point scale, where the
range between hospitals at baseline was 0.55 points.
Error rates/quality of acute medical care
Explicit review
SPI2 hospitals yielded 347 sets of case notes; 355 were
obtained fromcontrols (table 4).We found a significant
reviewer learning/fatigue effect (P=0.009) in the
review of prescribing errors, with a decreasing rate of
error detectionwith time of review; this was controlled
for in the analysis. Despite masking, the reviewer
became aware of the patient’s name in 1.1% (8) of
Table 4 | Medical history taking (% of patients asked required questions) before (epoch 1) and after (epoch 2) phase two of
Safer Patients Initiative (SPI2) and effect of SPI. Figures are percentages (binomial standard errors (SE)) and odds ratios
(99% confidence intervals) and P values for effect of SPI2
Control hospitals SPI2 hospitals
OR (99% CI)†, P value
Epoch 1
(n=120)
Epoch 2
(n=123)
Epoch 3*
(n=112)
Epoch 1
(n=116)
Epoch 2
(n=117)
Epoch 3*
(n=114)
Duration of “presenting” symptom 93 (2) 91 (3) 96 (2) 97 (2) 98 (1) 99 (1) 1.7 (0.07 to 40.3), 0.672
Normal exercise tolerance 27 (4) 32 (4) 38 (5) 39 (5) 38 (5) 34 (5) 0.7 (0.3 to 1.7), 0.312
Presence/absence shortness of breath 88 (3) 91 (3) 88 (3) 91 (3) 93 (2) 92 (3) 1.3 (0.3 to 5.7), 0.701
Presence/absence orthopnoea 23 (4) 28 (4) 17 (4) 33 (4) 29 (4) 18 (4) 0.9 (0.3 to 2.6), 0.749
Presence/absence cough 88 (3) 89 (3) 87 (3) 91 (3) 92 (3) 84 (4) 0.7 (0.2 to 2.4), 0.407
If cough present, was it productive 78 (4) 85 (3) 78 (4) 87 (3) 88 (3) 77 (4) 0.7 (0.2 to 2.1), 0.418
Smoking history taken 74 (4) 81 (4) 66 (5) 78 (4) 80 (4) 74 (4) 1.5 (0.5 to 4.0), 0.313
Presence/absence of haemoptysis 22 (4) 28 (4) 16 (4) 25 (4) 23 (4) 26 (4) 2.2 (0.7 to 6.5), 0.061
Chest pain (of any type) 68 (4) 72 (4) 55 (5) 54 (5) 66 (4) 60 (5) 2.1 (0.9 to 5.2), 0.028
Occupation/previous occupation 44 (5) 38 (4) 54 (5) 35 (5) 39 (5) 38 (5) 0.6 (0.3 to 1.5), 0.178
Pets at home 3 (2) 3 (2) 1 (1) 2 (1) 3 (2) 6 (2) 8.3 (0.3 to 210.0), 0.093
% over all items 56 58 54 68 59 57 —
*After intervention.
†OR >1 favours SPI2.
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Fig 1 | Rates of consumption of soap over time in control and
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cases; of hospital of origin in 0.4% (3) of cases; and of
epoch in 16.7% (117) of cases. Baseline comparisons
showed no significant differences between control
and SPI2 hospitals.
There was no apparent net additional effect of SPI2
and no significant effect for any of the end points mea-
sured (tables 5-7). For two items (exercise tolerance
and occupation)measured in relation to history taking,
there was significant evidence of an improvement in
hospitals over time. This occurred in both control
and SPI2 hospitals. 2
Compliance in taking observations of patients at 6
and 12 hours after admission also improved in both
groups of hospitals. This was most evident for respira-
tory rate, where practice continued to improve across
all three epochs. There was a considerable and signifi-
cant increase over time in use of the CURB score (a
clinical prediction rule for predicting mortality from
community acquired pneumonia, see table 6) (odds
ratio 7.3, 99% confidence interval 1.4 to 37.7), but
again differences were not significant between control
and SPI2 hospitals. Point estimates for six of the eight
standards formonitoring vital signs in the first 12 hours
after admission and for use of the CURB score
favoured SPI2 hospitals. There were no significant
effects of SPI2 either over time or in favour of SPI in
quality of prescribing (error rate ratio (estimated from
population averaged negative binomialmodel) 0.9, 0.5
to 1.5; P=0.444) (table 7). Further details, along with
tests for homogeneity of baseline end points among
control and SPI2 hospitals and the effect of covariates
are given in the full report. 2
Holistic review
A total of 725 sets of case notes were reviewed. In
epoch 1 we reviewed 126 sets from control hospitals
and 117 from SPI2 hospitals. The corresponding fig-
ures were 126 and 120 for epoch 2 and 114 and 122
for epoch 3. Agreement between the principal
reviewer and the reliability reviewer was low (κ=0.08).
A single patient could have more than one error. In
the control hospitals, the average number of errors per
100 patients decreased over the three epochs from 53
(epoch 1), to 40 (epoch 2), to 31 (epoch 3) per 100
patients. In the SPI2 hospitals, the average number of
errors per 100 patients was relatively stable over
epochs at 36, 45, and 39 per 100 patients. Differences
in changes in the average number of errors before and
after the intervention, across control and SPI2 hospi-
tals, were not significant (rate ratio 1.47, 0.74 to 2.90).
As in SPI1, diagnostic errors were the most common
type of error. In SPI2, however, errors in clinical rea-
soning were the second most common category,
exceeding medication error and hospital acquired
infections (see full report).2
Error rates/quality of perioperative care
We retrieved 242 sets of notes; 127 were from admis-
sions for total hip replacements and 115 from admis-
sions for open colectomies. One person reviewed
Table 5 | Vital signs in phase two of Safer Patients Initiative (SPI2). Figures are percentage compliance with standards with standard errors (SE) and odds
ratios for changes over time and effect of SPI2
Control hospitals SPI2 hospitals OR (99% CI)†, P value
Epoch 1
(n=120)
Epoch 2
(n=123)
Epoch 3*
(n=112)
Epoch 1
(n=116)
Epoch 2
(n=117)
Epoch 3*
(n=114) Changes in controls Effect of SPI2
On admission
Temperature 97 (2) 99 (1) 99 (1) 99 (1) 99 (1) 97 (2) 0.7 (0.02 to 24.0), 0.823 0.1 (0.002 to 4.1), 0.108
Respiratory rate 96 (2) 99 (1) 100 97 (2) 98 (1) 100 NA NA
Cyanosis/oxygen saturation 98 (1) 98 (1) 100 99 (1) 99 (1) 100 NA NA
Confusion/mental state 53 (5) 72 (4) 74 (4.2) 63 (5) 57 (5) 81 (4) 1.8 (0.8 to 3.7), 0.045 1.7 (0.6 to 4.5), 0.187
Pulse 98 (1) 99 (1) 100 99 (1) 99 (1) 100 NA NA
Blood pressure 98 (1) 99 (1) 100 99 (1) 99 (1) 100 NA NA
At 6 hours
Temperature 62 (5) 70 (4) 70 (4) 63 (5) 78 (4) 68 (4) 1.4 (0.7 to 2.8), 0.239 0.8 (0.3 to 1.9), 0.457
Respiratory rate 41 (5) 69 (4) 72 (4) 47 (5) 76 (4) 78 (4) 2.1 (1.0 to 4.3), 0.010 1.0 (0.4 to 2.8), 0.907
Pulses 69 (4) 73 (4) 75 (4) 65 (5) 81 (4) 80 (4) 1.3 (0.6 to 2.8), 0.327 1.2 (0.4 to 3.3), 0.662
Oxygen saturation 62 (5) 72 (4) 74 (4) 61 (5) 79 (4) 80 (4) 1.4 (0.7 to 3.0), 0.223 1.2 (0.4 to 3.1), 0.703
At 12 hours
Temperature 58 (5) 71 (4) 69 (4) 59 (5) 70 (4) 73 (4) 1.2 (0.6 to 2.4), 0.583 1.2 (0.5 to 2.9), 0.685
Respiratory rate 35 (4) 70 (4) 73 (4) 45 (5) 68 (4) 79 (4) 2.4 (1.1 to 5.0), 0.002 1.2 (0.4 to 3.1), 0.713
Pulse 63 (4) 76 (4) 75 (4) 60 (5) 71 (4) 80 (4) 1.2 (0.6 to 2.5), 0.510 1.5 (0.6 to 4.1), 0.268
Oxygen saturation 54 (5) 76 (4) 74 (4) 57 (5) 71 (4) 80 (4) 1.4 (0.7 to 2.9), 0.231 1.4 (0.5 to 3.6), 0.430
Routine investigations
Urea and electrolytes 99 (1) 98 (1) 99 (1) 100 99 (1) 100 0.6 (0.01 to 27.7), 0.762 NA
Chest x ray 97 (2) 98 (1) 97 (2) 97 (2) 98 (1) 100 0.7 (0.1 to 5.6), 0.641 NA
Full blood count 98 (1) 98 (1) 99 (1) 99 (1) 99 (1) 100 1.7 (0.1 to 40.4), 0.663 NA
NA=not applicable because of 100% in cells.
*After intervention.
†OR >1 favours SPI2. No items showed significant variation between hospitals within arms.
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these; a second reviewer also examined a sample of 27.
Percentage agreementwas 93% for antibiotics and 96%
for deep vein thrombosis prophylaxis, but κ values
could not be calculated because one reviewer put all
cases in the same category. Agreement was 85% and
59% for pain relief and temperature monitoring, with
corresponding κ values of 0.46 and 0.24. The hospitals
were similar at baseline, except with respect to intra-
operative monitoring of temperature, where controls
had more room for improvement.
Therewas little room for improvement for two of the
four standards examined. For antibiotic prophylaxis,
compliance exceeded 94% in all cases; for deep vein
thrombosis prophylaxis, compliance exceeded 98% in
all cases. Intraoperative monitoring of temperature
improved over time in both groups, although this
result was not significant (odds ratio 1.8, 0.4 to 7.6;
P=0.279). There were no significant SPI2 effects for
any of the four clinical standards examined (table 8).
Indirect measure of hand hygiene
Data on consumption of soap and alcohol hand rub
were available from epochs 1 and 2 for nine and eight
of the control trusts and for seven and six of the SPI2
trusts, respectively. Rates of consumption increased in
both control and SPI2 hospitals over the study period
(figs 1 and 2), suggesting considerable improvement.
The rate of increase in consumption (that is, differences
in differences), however, was not significantly greater
in the SPI2 hospitals than in the control hospitals
(P=0.760, favouring controls, and P=0.889, favouring
SPI2, respectively).
Outcomes
Adverse events in patients on acute medical wards
The holistic review identified adverse events among
patients on acute wards. Reliability between raters
was no better than chance (κ=0.0). Over all hospitals
and all epochs, the principal reviewer identified 22
adverse events among the 725 sets of case notes, giving
an average adverse event rate of 3.03 per 100 patients.
In the control hospitals, the average number of adverse
events per 100 patients decreased over the three
epochs, from 4.8 per 100 patients in epoch 1, to 4.0
(epoch 2), and 3.5 (epoch 3). In contrast, in the SPI2
hospitals the average number of adverse events per
100 patients increased from 0.9 per 10 in epoch 1 to
5.0 per 100 in epoch 2, but decreased to zero in
epoch 3. Again, differences in the change in numbers
of adverse events across control and SPI2 hospitals
were not significant (rate ratio 1.47, 0.74 to 2.90).
The principal reviewer identified strong or certain
evidence of preventability in four of the 22 adverse
events (that is, 0.5% of cases overall). These four
adverse events occurred in the epochs before the inter-
vention (see the companion paper1).
Mortality in acute medical patients in case note review
Ninety seven of the 702 patients included in the expli-
cit review of acutemedical care died (14%) (table 9). At
baseline crude mortality was higher in the control hos-
pitals than in the SPI2 hospitals (odds ratio 0.7, 0.2 to
2.1; P=0.391).Neither this, nor any other effect, includ-
ing that of the SPI, was significant at the predetermined
1% level after adjustment for age, sex, and number of
comorbidities (0.3, 0.08 to 1.4), although the result was
just significant (P=0.043) at the 5% level. The odds ratio
Table 6 | Use of systemic steroids, CURB score, and other standards applicable to specific cases—compliance with standards
in phase two of Safer Patients Initiative (SPI2). Figures are numbers (percentage, SE) and odds ratios (99% confidence
interval) and P values for effect of SPI2
Standard
Control hospitals SPI2 hospitals
Effect of SPI2†Epoch 1 Epoch 2 Epoch 3* Epoch 1 Epoch 2 Epoch 3*
Asthma or COPD: steroids given
within 24 hours
70 (84, 4) 63 (92, 4) 56 (93, 4) 59 (92, 4) 74 (93, 3) 53 (94, 3) 0.6 (0.05 to 6.8), 0.568
Asthma: peak flow recorded 10(80,13) 11(64,15) 5 (40, 22) 24 (79, 8) 18 (94, 5) 8 7 (5, 15) 29.7 (0.1 to 16000), 0.165
Community acquired pneumonia:
CURB score recorded
52 (2, 2) 67 (22, 5) 56 (21, 6) 50 (2, 2) 44 (25, 6) 60 (42, 6) 2.1 (0.4 to 11.1), 0.236
COPD=chronic obstructive pulmonary disease; CURB=confusion/urea/respiratory rate/blood pressure score.
*After intervention.
†OR >1 favours SPI2. No items showed significant variation between hospitals within arms.
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Fig 2 | Rates of consumption of alcohol hand rub over time in
control and SPI2 hospitals
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for change in controls was 1.4 (0.06 to 3.1; P=0.320).
Sex and number of comorbidities were included as
patient level covariates, but only age was significant
(P<0.001). The mortality rate increased by 10.3%
(6.8% to 15.1%) per year of patient age.
In the holistic review we reviewed notes from 725
patients (compared with 702 in the explicit review).
Of these, 91 (13%) died. The principal reviewer (MC)
found potentially preventable factors in six of these
cases and the second reviewer (MCD) also found six;
five caseswere common to both reviewers. The second
reviewerwasmore “hawkish,”however, placing five of
her six cases in the category of 50% or greater likeli-
hood of preventability—that is, she concluded that it
was more likely than not that death during the hospital
stay couldhavebeenpreventedhad the putative failure
in care not occurred. The principal reviewer was
“dove-like,” placing all of his cases in the “less than
50%” category. Table 10 gives a breakdown of deaths
by level of preventability and reviewer. The total per-
centage of high (>50%) preventability deaths common
to both reviewers was 5% (5.5% of deaths). They iden-
tified seven (7.7% of deaths) deaths with any potential
preventable factors.
Mortality in intensive care units
Seven control and seven SPI2 hospitals supplied data
to ICNARC for the period before the intervention per-
iod and six control and eight SPI2 hospitals for after the
intervention. Based on length of stay, intensive care
units in control hospitals might have been dealing
with a different case mix to the SPI2 hospitals.
APACHE and ICNARC scores were similar, how-
ever, and not significantly different between groups
and over time. The rate of observed to expected mor-
tality increased in the control hospitals and decreased
in the SPI2 hospitals over the study period (table 11).
The adjusted difference in difference was not signifi-
cant (P=0.250). 2
Infection control: rates of C difficile and MRSA
Data on the numbers of cases of C difficile and MRSA
were available for all 18 trusts. The infection rate for C
difficile decreased over the study period in both the
control and SPI2 hospitals. The point estimate favours
SPI2 hospitals, but differences in changes were not sig-
nificant between control and SPI2 hospitals (P=0.652).
Figure 3 shows the smoothed estimated rates ofC diffi-
cile infection per 1000 bed occupied days by control
and SPI2 hospitals.
The median infection rate of MRSA also decreased
over the study period in both the control and SPI2 hos-
pitals. Again, it was not possible to detect an effect of
SPI in this improvement: differences in changes were
not significant between control and SPI2 hospitals
(P=0.693) although the point estimate favours SPI2.
Figure 4 outlines the estimated smoothed rates of
MSRA infection per 100 000 bed occupied days by
control and SPI2 hospitals.
Survey of patients
For the first survey, the overall response rate was 62%
(4328 of 7010 valid questionnaires returned) in the
nine SPI2 hospitals; for the second it was slightly
lower at 55% (3762/6810). In the nine control hospi-
tals, the response rates were 63% (4262/6791) and 57%
(3973/6913), respectively. Table 12 shows the changes
Table 7 | Analysis of prescribing errors before (epoch 1) and after (epoch 3) phase two of Safer Patients Initiative (SPI2)*
Control hospitals SPI2 hospitals
Epoch 1 Epoch 2 Epoch 3† Epoch 1 Epoch 2 Epoch 3†
No of patients‡ 120 122 112 113 117 114
No of prescriptions 2953 3269 2871 2529 2938 2656
Prescriptions per patient 24.6 26.8 25.6 22.4 25.1 23.3
No of errors 345 298 216 251 266 167
Error rate (SE) per prescription 0.12 (0.02) 0.09 (0.01) 0.08 (0.01) 0.101(0.02) 0.09 (0.01) 0.06 (0.01)
*Breakdown of error types, including failure to reconcile patient’s previous medicines with prescription on admission (particular focus of SPI),
available in full report (www.haps.bham.ac.uk/publichealth/psrp/EvalSPI.shtml).2
†After intervention.
‡With medication charts available for review.
Period
N
o 
of
 c
as
es
 o
f C
 d
iff
ic
ile
N
o 
of
 c
as
es
 o
f C
 d
iff
ic
ile
Control hospitals
Jan
2004
Jul
2006
Apr
2005
Oct
2007
Apr
2011
Jan
2009
0
0.4
0.8
1.2
1.6
2.0
0.4
0.8
1.2
1.6
2.0
Hospital averages
Model fit
99% CI
SPI2 hospitals
0
Fig 3 | Rates of cases of C difficile per 1000 bed days in control
and SPI2 hospitals
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in both control and SPI2 hospitals on each of the five
scores identified, along with the differences between
the groups in these changes and associated 99% confi-
dence intervals. All five scores improved over the
study period in both the control and SPI2 hospitals;
none showed any significantly different changes
between the two groups.
DISCUSSION
Commentaries on patient safety in the United States
five years after the publication of two key reports on
patient safety in 2000 were characterised by some des-
pair at an apparent lack of progress.19 Our data suggest
that a more encouraging story on patient safety in the
NHS can now be told.
Baseline performance across hospitals was already
high on many criteria relating to quality, leaving little
room for improvement. Over 90% of patients with an
acute exacerbation of obstructive airways disease
received steroids when indicated, and rates of perio-
perative prophylaxis against venous thrombosis and
infection approached 100%, corroborating an earlier
study.20 Where scope for improvement existed, we
found many examples of improved, and none of wor-
sening, practice. Vigilance in relation to monitoring
vital signs on acute medical wards and use of severity
scoring, observed in our study of SPI1, continued to
improve. A strong upward trend in recording intra-
operative temperature was noted. Rates of handwash-
ing seemed to have increased significantly, and the
incidence of C difficile and MRSA infection fell.
Though results of the staff survey showed little change
over time, the survey of patients showed improvement
across all five prespecified dimensions, suggesting a
better experience for patients. There was even an
improvement in medical history taking. Adverse
event rates (3.03% in our study) seemed similar to
those reported in the Harvard medical practice study
(3.7%), which was based on data collected in 1984.21
We found low levels of preventability among adverse
events overall (about 20%) and amongdeaths (less than
10%). If these findings are corroborated, they have
implications for future evaluations and performance
management, as the signal (preventable adverse
events) seems to be buried in a lot of noise (non-pre-
ventable adverse events).
The data we collected on SPI2 suggest that an addi-
tional effect of SPI is difficult to detect over and above
the improvements occurring across the health service
generally. Indeed, in a reversal of our evaluation of
SPI1, organisational climate as measured by the staff
survey favoured the controls. Adherence rates for
many of the specific criteria reflecting quality of care
remained high over time in both groups of hospitals,
possibly reflecting a long history of quality improve-
ment in areas such as perioperative care. Those areas
that underwent marked improvement did so to a simi-
lar degree in both sets of hospitals. One exception was
the drop in mortality among acute medical cases in
SPI2 hospitals and an unexplained rise in control hos-
pitals, such that the difference in differences would
Table 8 | Rates of compliance with perioperative care standards before (epoch 2) and after (epoch 3) phase two of Safer
Patients Initiative (SPI2). Figures are percentages (standard error (SE)) and odds ratios and P values for effect of SPI2
Control hospitals SPI2 hospitals
OR (99% CI)*, P value
Before
intervention
(n=51)
After
intervention
(n=43)
Before
intervention
(n=79)
After
intervention
(n=69)
“Advanced method” of pain relief† 94 (4) 95 (4) 85 (4) 83 (5) 0.8 (0.03 to 18.4), 0.820
Perioperative antibiotic given 94 (3) 100 98 (2) 97 (2) NA
Temperature monitored‡ 16 (5) 30 (7) 29 (5) 41 (6) 0.9 (0.1 to 5.2), 0.854
Appropriate DVT prophylaxis§ 100 100 99 (1) 100 NA
DVT=deep vein thrombosis; NA=not applicable because of 100% in cells.
*OR >1 favours SPI2.
†Hospital staff identified 15 cases with contraindications to this standard, all of which were corroborated by reviewers. Data relate to 227 patients
who were eligible.
‡ Evidence of heterogeneity between hospitals at baseline.
§ Three patients had contraindications yielding denominator of 238. Withheld in only two patients with no contraindications but wrongly administered
in two patients with contraindication.
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have been just significant if we had selected a P<0.05
threshold. Any suggestion of a difference in mortality
rates resulting from difference in the quality of care,
however, does not align well with the review of the
quality of care observed among those same case
notes. The observed difference in overall mortality
cannot be accounted for by a difference in preventable
deaths as only seven of the 91 deaths fell into the pos-
sibly preventable category. Overall, though there is
considerable evidence of good or improved quality
and safety in NHS hospitals, we could not detect a net
effect attributable to SPI2 with our study measures.
This largely mirrors the evaluation of SPI1,1 though
the latter did show an effect of SPI on the quality of
monitoring the respiratory rate. Table 13 summarises
the effects of both phases of SPI versus control, in terms
of direction of the point estimate and degree of signifi-
cance.
Strengths and weaknesses of this study
The argument wemade in the companion article,1 and
elsewhere,3 that studies of quality improvement inter-
ventions should followpredefinedprotocols and incor-
porate contemporaneous controls is reinforced by our
study of SPI2, where many end points improved sig-
nificantly across both SPI2 hospitals and controls. We
have also shown the importance of using a difference in
difference approach to analysis to overcome the ambi-
guities of single difference studies. This method is
widely used in economics research, where there are
policy and other changes occurring during the imple-
mentation of a programme,22 and it is clearly suitable
for evaluations of quality improvement programmes
in healthcare. We have also shown the need to allow
for learning/fatigue effects in reviewing.
A particular strength of our study arises from its pos-
sibilities for triangulation. While available funding did
not permit us to build further qualitative studies into
the design, we did have various internal controls. Find-
ings on the use of handwashing materials and rates of
two different types of infection support the hypothesis
of general improvement in this area. The observation
that vital signs were recordedwith increasing diligence
and that risk scoring was used more often supports the
idea that patients at risk of deterioration were being
monitored more diligently. Mortality rates on acute
medical wards could be triangulated, not only by an
audit of compliance with process standards, but also
by scrutinising each death in the sample to see if it
could have been caused by poor care.
With hindsight, there are some things that we would
do differently in this study. We would not measure all
prescribing errors as this is expensive, andmany errors
are minor and of uncertain validity as surrogates for
Table 9 | Mortality among acute medical care patients whose case notes were explicitly reviewed before (epoch 1) and after
(epoch 3) phase 2 of Safer Patients Initiative (SPI2)
Control hospitals SPI2 hospitals
Epoch 1 Epoch 2 Epoch 3* Epoch 1 Epoch 2 Epoch 3*
No of patients 120 123 112 116 117 114
Deaths 18 24 24 9 15 7
% mortality (SE) 15 (3.3) 20 (3.6) 21 (3.9) 8 (2.5) 13 (3.1) 6 (2.3)
Mean (SD) age (years) 77.6 (7.7) 81.1 (7.9) 79.6 (8.0) 77.7 (7.6) 78.1 (7.1) 80.6 (7.8)
% women 63.3 53.7 53.6 53.4 50.4 52.6
Mean No of comorbidities 2.9 3.1 2.6 2.8 3.0 2.9
*After intervention.
Table 10 | Preventable deaths among acute medical care cases where notes were reviewed holistically across study epochs
before (epoch 1) and after (epoch 3) phase two of Safer Patients Initiative (SPI2)
Epoch
No of deaths
(cases
reviewed)
Preventable deaths ≥50%* Preventable deaths <50%†
1st reviewer
only
2nd reviewer
only
Both
reviewers
1st reviewer
only
2nd reviewer
only
Both
reviewers
Control hospital
1 17 (126) 0 0 1 0 0 1
2 24 (126) 0 0 1 1 0 1
3‡ 23 (114) 0 0 2 0 1 2
Total 64 (366) 0 0 4 1 1 4
SPI2 hospitals
1 9 (117) 0 0 0 0 0 0
2 11 (120) 0 0 1 0 0 1
3‡ 7 (122) 0 0 0 0 0 0
Total 27 (359) 0 0 1 0 0 1
*Preventable deaths ≥50%: on balance of probabilities substandard practice led to death.
†Preventable deaths <50%: substandard practice could have led to death but probability that it did was <50%.
‡After intervention.
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serious error.23 We would instead concentrate on
errors whose serious nature had been established.
The reliability reviewer was new to case note reviews,
and although several training sessions took place we
would approach this training more systematically in
the future. Nevertheless, previous work has also
found that reliability for holistic reviews is lower than
reliability for explicit reviews.24
We are developing and evaluating a novel tool based
on review of case notes of patients who die in hospital,
where eachdeath is scoredona sliding scale of prevent-
ability. The aim is to produce a reliable measure of the
proportion of hospital deaths that are preventable.
Possible improvements in clinical areas not studied
Though we had an explicit rationale for the clinical
areas in which we focused our study, improvements
could have occurred in areas that we did not study,
such as ventilator acquired pneumonia and central
line infections in intensive care units. If improvements
did occur in these areas, it is possible that a greater
“dose” of SPI was administered in these settings (for
example, more activity by SPI “change agents”) or
that such settings were more responsive to change
than those we studied.
Improvements below the level of statistical detection
The absence of an additive SPI effect detected by our
study does not exclude smaller effects that might none
the less be cost effective. The threshold in England
under which an intervention is judged cost effective is
about £30 000 (€35 000; $48 000) per quality adjusted
life year (QALY). The SPI would, therefore, need to
save fewer than seven lives with a mean duration of
five healthy years (ignoring discounting) to justify the
SPI1 investment of £775 000 per hospital (and an even
smaller magnitude of effect would be cost effective at
the smaller costs in SPI2 hospitals). An effect of this
magnitude cannot be excluded in a study of any feasi-
ble size; with many hundreds of deaths taking place in
each hospital in each year the signal would be lost in
the noise.25 None the less, large effects postulated in
advance of the study have been excluded, at least in
the areas examined. The study was, after all, large
enough to detect temporal improvements. The 50%
and 30% reductions in adverse events that were aims
of SPI1 and SPI2, respectively, were unnecessarily
large in the sense that much smaller effect sizes would
justify the costs of the intervention.
SPI hospitals might have been less sensitive to the
intervention
The studywas not randomised, andwe cannot exclude
the possibility that SPI hospitals as a whole were less
sensitive to the intervention than controls. There were
few differences at baseline, however, and where there
was room for improvement among controls, similar
room was available for SPI hospitals. It is also possible
that SPI works better in some types of hospital than
others.26 We did not have statistical power to test for
such interactions.
Possible suboptimal specification or implementation of SPI
Some of the reasons for the absence of an additional
detectable SPI effect might lie in the design and imple-
mentation of the programme. While interviews con-
ducted with senior staff in the study of SPI11
emphasised the “bottom-up” nature of the inter-
vention, this was not necessarily how it was perceived
by most ward staff. Despite the enthusiasm and broad
understanding of the principles underlying the SPI at a
strategic level, the programme and organisational the-
ories of change might not have been sufficiently expli-
cit. For example, no formal protocol for the
intervention was published. There is evidence from
the qualitative work in SPI1 that the scale of the SPI
taskwas perceived as huge anddemandingof resource.
There were also suggestions that there was a need for
the programme to be purposefully and actively led in
each clinical setting, rather than assuming spontaneous
“spread” from one setting to another. More work
before the intervention might have identified with
more precision how and under what conditions the
programme would work best and would have more
completely specified the underlying theories.
Optimising design and execution of quality
improvement programmes is clearly necessary for
many reasons, not least to avert the risk of damaging
the credibility of such programmes as a whole. A com-
bination of a more explicit programme theory and
organisational theory of change, including better spe-
cification of the method of vertical and horizontal
spread, might, for example, have explicitly confronted
the six “universal challenges” for quality improvement
(structural, political, cultural, educational, emotional,
Table 11 | Intensive care outcomes in phase two of Safer Patients Initiative (SPI2). Median and interquartile ranges for control
and intervention hospitals, before and after intervention period*
Intensive and critical
care outcomes*
Control hospitals SPI2 hospitals Difference in difference
Before After Before After Change (99% CI)† P value
Adjusted mortality ratio 1.14 (0.99-1.32) 1.24 (1.02-1.33) 1.04 (0.90-1.15) 0.97 (0.90-1.15) 0.09 (−0.11 to 0.29) 0.25
Mean LOS (hours) 144 (117-174) 147 (126-185) 102 (82-130) 103 (81-137) 5.86 (−22.78 to 34.50) 0.60
Mean APACHE II score 20.4 (17.7-22.6) 19.0 (17.1-20.8) 21.1 (19.1-23.0) 20.3 (17.8-21.8) −0.83 (−3.63 to 1.98) 0.459
Mean ICNARC score 22.3 (19.5-26.3) 20.7 (18.0-23.5) 22.6 (21.2-25.3) 22.2 (19.7-25.1) −2.26 (−6.39 to 1.87) 0.16
LOS=length of stay; APACHE=acute physiological and chronic health evaluation; ICNARC=Intensive Care National Audit and Research Centre.
*Before period is October 2006 to March 2007 and after period is October 2008 to March 2009.
†Change <1 favours SPI2.
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and physical/technological),27 and it might have
focused more attention on ensuring clinical engage-
ment and use of clinical networks. Such an approach
might have encouraged an earlier recognition that the
intervention was broad relative to resources andmight
have identified that effects were likely to be localised in
response to “dose” of intervention. In that case a more
focused and less ambitious intervention, and some-
what narrower evaluation, might have been a better
strategy.
There is also an argument that participation in SPI
could secure greater long term commitment to quality
and safety in participating hospitals and that improve-
ments made in the intervention hospitals will either
surface at a later date or be sustained better. This
hypothesis can be tested only with further data collec-
tion, but it is possible that any effect of SPI might be in
the form of “stickiness”; intervention hospitals might
potentially be better equipped to show sustained
improvements after the policy spotlight has moved
elsewhere.
Contemporaneous policy and professional forces in the
control environment
SPI coincided with a period of unprecedented increase
inNHS funding that couldhave contributed tomanyof
the improvements observed. An important reason for
the absence of an additional effect of SPI might lie in
the extent of the policy level programmes and initia-
tives that were largely contemporaneous with the SPI,
shared some of its goals, principles, and methods, and
acted forcefully on the control environment. For exam-
ple, the “cleanyourhands” campaign promoted the
same goal of improved hand hygiene as the SPI and
began around the same time. In addition, the Health
Act 2006 introduced new legislation on mandatory
requirements for prevention and control of infections
associated with healthcare and is likely to have exerted
further pressures on hospitals.
Perhaps most importantly, several initiatives with
features similar to IHI-style techniques and principles
had increasing impact on policy at around the time that
the SPI (which was mentored by the IHI) was
launched. For example, the Department of Health’s
Saving Lives programme, beginning in June 2005
with a revised version in 2007,28 included a self assess-
ment tool for trusts to assess their managerial and clin-
ical performance and a set of “high impact
interventions” that were similar to the IHI bundles
and were aimed at several clinical processes also tar-
geted by the SPI. The interest in IHI-like interventions
might indeed have been prompted or inspired at least
in part by the SPI; the House of Commons committee
report on patient safety, for example, lists the SPI’s
beginning in 2004 as among the important policy
developments in the patient safety timeline.29 It is
also relevant that many of these policy initiatives had
already been anticipated by consensus in professional
societies and medical colleges, and thus enjoyed con-
siderable professional legitimacy—a crucial factor in
promoting safe and effective practice.30 Patient safety
and quality improvement was also, during the period
when SPI was being implemented, drawing increasing
attention from journals, professional meetings, and
conferences. The SPI programme was thus being
implemented at a time when the momentum towards
quality improvement was accelerating and when it
might itself have been one of the forces implicated in
the momentum.
Given that many of the changes in practice being
urged at a policy level were so similar to the SPI, and
the resource directed at the SPI was relatively small,
the SPI itself might not have been a sufficient addi-
tional “dose” to generate further detectable differences
in participating hospitals: from £270 000 to £775 000
spent over 18 months in hospitals with annual budgets
of £150m to £300m might simply be too small. This is
perhaps most vividly illustrated by the disappearance
Table 12 | Patient survey scores* in control and SPI2 hospitals before (survey 1) and after (survey 2) phase two of Safer Patients Initiative (SPI2)
Control hospitals SPI2 hospitals
Range at
baseline
Effect ofSPI2
(99%CI)†‡, P
value
Survey 1 Survey 2 Abso-
lute %
change
Survey 1 Survey 2 Abso-
lute %
change
No of
patients
Score
(SE)
No of
patients
Score
(SE)
No of
patients
Score
(SE)
No of
patients
Score
(SE)
Overall, how would you rate the
care you received?
4200 82 (0.4) 3913 85 (0.3) 4 4277 80 (0.4) 3705 84 (0.3) 4 75-87 1 (−1 to 3),
0.292
Overall, did you feel you were
treated with respect and dignity
while you were in the hospital?
4111 78 (0.4) 3807 82 (0.4) 4 4167 76 (0.4) 3604 80 (0.4) 3 65-85 0 (−2 to 2),
0.702
Howwouldyou ratehowwell the
doctors and nurses worked
together?
4182 87 (0.4) 3878 88 (0.4) 1 4220 88 (0.4) 3677 89 (0.4) 1 83-91 0 (−2 to 2),
0.597
In your opinion, how clean was
the hospital room or ward that
you were in?
4113 75 (0.4) 3870 77 (0.4) 2 4201 77 (0.4) 3645 78 (0.4) 1 70-80 −1 (− to 1),
0.141
How clean were the toilets and
bathrooms that you used in
hospital?
4141 76 (0.4) 3877 78 (0.4) 2 4220 78 (0.4) 3665 79 (0.4) 1 70-82 −1 (−3 to 1),
0.204
*Mean values of five survey scores in control and SPI2 hospitals for first and second patient surveys, rated between 0-100.
†Values >1 favours SPI2.
‡Values differ from simple subtraction because of rounding.
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in SPI2 of the positive impact on measures of compli-
ance with monitoring and response to vital signs dete-
rioration that we found in SPI1. This probably
occurred because guidelines on recognition and
response to acutely ill patients were issued by the
National Institute for Health and Clinical Excellence
(NICE) in 2007,31 just as SPI2 was getting started. The
detectable effects of SPI could have been muted com-
pared with a situation where no similar policy changes
were occurring.
In clinical research it has long been known that out-
comes tend to improve over time, with the result that
before and after studies systematically exaggerate
treatment effects compared with studies with contem-
poraneous controls.32 In clinical research temporal
trends are usually the result of various factors apart
from the intervention of interest, although exceptions
exist—for example, HIV drugs and prostate specific
antigen screening diffused into widespread use before
evaluations were complete.33 34 This risk of pre-evalua-
tion diffusion is arguably greater in the case ofmanage-
ment interventions that are multi-faceted, not easily
containable, and are promoted as part of “continuous
improvement” strategies. While new medicines are
generally evaluated before they can be licensed and
adopted, service interventions can more easily come
into general use and generate social reinforcement
before a formal evaluation has been put in place.
Indeed growing interest in the intervention might be
the stimulus both for increasing adoption and for the
evaluation. The evidence provided above suggests that
something like that happenedwith SPI andmight have
occurred in the provocatively null result of theMERIT
study of rapid response service on medical wards.35
Our results suggest the occurrence of a phenomenon
where the measured effect of an intervention is attenu-
ated by similar changes happening more generally.
This should be distinguished from the phenomenon
of contamination, where the control group receives
(some of) the intervention targeted at the study
group.36 In the case of the SPI, “contamination” is an
inappropriate descriptor as the studywas “anamnestic”
and controlswere selected after the SPI had beenput in
place. SPI implementation was well under way when
controls were selected and the controls were not
exposed to the extensive and expensive mentoring
process that SPI entailed. We propose, rather, that a
“rising tide” phenomenon was at work; both control
and SPI sites were subject to the same tidal forces,
and these same latent factors were the source of both
a change in practice and the perceived need to evaluate
these changes. Under these circumstances it is still
worth evaluating an intervention, but this is more
akin to evaluating “dose” in clinical research; the idea
is pragmatic and aims to find out whether the marginal
gains of an extra “push” is worthmarginal expenditure
or, at least, to provide some evidence to inform such a
judgment.
Conclusions
Our studies show encouraging signs of improvements
in quality and safety in the NHS in England, but
detected only one specific improvement as a result of
SPI, and that was confined to the first phase of the
Table 13 | Summary of directions of effects of SPI across all quantitative evaluations of SPI1 and SPI2. Significant results are
indicated
SPI1 v control SPI2 v control
Outcomes
favouring SPI
Outcomes
favouring
control
Outcomes with
no difference
Outcomes
favouring SPI
Outcomes
favouring
control
Outcomes with
no difference
Staff survey 7* 3 1 2 10* 1
Vital signs 9* 3 2 7 2 4
Routine investigation 0 3 — — — 3
Specific standards 0 3 — 2 — —
Prescribing — 1 — 1 — —
Medical history 5 5 1 6 5 1
Mortality among casenotes 1 — — 1 — —
Holistic errors 1 — — — 1 —
Holistic adverse events 1 — — — 1 —
Patient survey 4* 1 — 1 2 2
Intensive care mortality NA NA NA 1 — —
Handwashing materials:
Soap NA NA NA — 1 —
Alcohol hand rub NA NA NA 1 — —
C difficile rates NA NA NA 1 — —
MRSA rates NA NA NA 1 — —
Totals 28 19 4 24 22 11
NA=Not applicable
*One of these results was significant at P<0.01. Across whole study, four of 108 measured outcomes yielded significant results at P<0.01 when
changes in SPI were compared with changes in control. Three of these favoured SPI and one favoured controls. Four further results were significant at
P<0.05, but not P<0.01; and all favoured SPI (three in SPI1 and one in SPI2).
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programme. Any detectable effects of such inter-
ventionsmight take time to surface. Such interventions
are likely to benefit from clarity about the theories of
change underlying the programme, recognition of the
scale of resource and organisational support required
to make patient safety efforts work, and improved
understanding of how practitioners, middle managers,
and organisational systems can be better supported in
the face of daunting complexity andmultiple priorities.
Robust methods are needed to make appropriate con-
clusions about the impact of quality improvement
efforts.
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